Norli Liv & Pension Modernizes Investment Operations with Clearwater Analytics
BOISE, Idaho & CHICAGO & NEW YORK & LONDON--(BUSINESS WIRE)--May 14, 2025--
Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today announced that Danish pension provider, Norli Liv & Pension, part of the Norli group, has partnered with Clearwater to modernize its investment accounting, reporting and compliance operations.
Clearwater will provide Norli with a single, consolidated view of all in-house and outsourced chief investment officer (OCIO) managed holdings across its public and private asset classes—enhancing investment transparency and empowering better, faster decision-making. The platform will also support regulatory compliance through automated workflows and robust, audit-ready reporting.
By moving to Clearwater's single instance, multi-tenant platform, Norli Liv & Pension will eliminate multiple legacy platforms, reduce manual work and accelerate its monthly close. The platform's 'single pane of glass' view will provide users across departments with unified access to accurate, timely data and analytics across all asset classes. Additionally, Clearwater's scalability and flexibility will enable Norli to adapt to evolving Danish regulatory reporting requirements in real time.
'Partnering with Clearwater Analytics is a major step forward for our business,' said Peter Trägårdh Christensen, Group Director at Norli Liv & Pension. 'We're adopting a modern solution that simplifies regulatory complexity and enhances the quality of our financial reporting. Clearwater's platform provides the efficiencies needed to innovate, scale confidently and meet client and regulatory reporting expectations with reliable data.'
'We're proud to support Norli Liv & Pension as they modernize their investment operations,' said Keith Viverito, Managing Director EMEA at Clearwater Analytics. 'Their decision highlights a broader shift among pension providers toward data consolidation and automation. With Clearwater, Norli Liv & Pension can streamline operations and confidently navigate Denmark's regulatory landscape. We look forward to being a long-term partner in their continued growth.'
Discover how Clearwater Analytics can elevate your investment management strategy and drive operational excellence by speaking to an expert today.
About Norli Liv & Pension
Norli Group is a Nordic consolidator of traditional guaranteed life and pension products that uniquely offers new customers traditional pension savings as part of their pension scheme. Founded in 1986 as part of Alm. Brand Group (formerly Alm. Brand Life and Pension), the company rebranded to Norli Liv & Pension under new ownership in 2022. Now part of Nordic I&P, which focuses on pension insurance across the Nordics, Norli Liv & Pension aims to be the market leader in traditional pension savings.
About Clearwater Analytics
Clearwater Analytics (NYSE: CWAN) is transforming investment management with the industry's most comprehensive cloud-native platform for institutional investors across global public and private markets. While legacy systems create risk, inefficiency, and data fragmentation, Clearwater's single-instance, multi-tenant architecture delivers real-time data and AI-driven insights throughout the investment lifecycle. The platform eliminates information silos by integrating portfolio management, trading, investment accounting, reconciliation, regulatory reporting, performance, compliance, and risk analytics in one unified system. Serving leading insurers, asset managers, hedge funds, banks, corporations, and governments, Clearwater supports over $8.8 trillion in assets globally. Learn more at www.clearwateranalytics.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250514122779/en/
CONTACT: Media:
Claudia Cahill, Head of Communications and PR | +1 208-433-1200 |[email protected]
KEYWORD: NORTH AMERICA UNITED STATES UNITED KINGDOM EUROPE DENMARK ILLINOIS IDAHO NEW YORK
INDUSTRY KEYWORD: PROFESSIONAL SERVICES DATA MANAGEMENT DATA ANALYTICS TECHNOLOGY SOFTWARE FINTECH ACCOUNTING
SOURCE: Clearwater Analytics
Copyright Business Wire 2025.
PUB: 05/14/2025 03:00 AM/DISC: 05/14/2025 02:59 AM
http://www.businesswire.com/news/home/20250514122779/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Clayco CEO sees cautious clients, smarter investments
This story was originally published on Construction Dive. To receive daily news and insights, subscribe to our free daily Construction Dive newsletter. One of Chicago's largest construction companies remains confident in the data center and advanced manufacturing project pipeline, according to its CEO. In May, Clayco made a slate of key leadership promotions, including Ryan McGuire as president of construction and new national roles for several division leaders, according to a release. The moves aim to strengthen project delivery across key sectors including life sciences, e-commerce and institutional work, according to the company. Meanwhile, Clayco continues to ramp up its data center construction efforts with its new business unit, Clayco Compute, said CEO Anthony Johnson. The design-build firm generated $3.6 billion in 2024 from data center projects, accounting for half of the company's total revenue, according to Clayco. Here, Johnson talks with Construction Dive about Clayco's growth outlook for the second half of 2025, cost pressures and overall uncertainty in the construction industry. This interview has been edited for brevity and clarity ANTHONY JOHNSON: In the second half of 2025, we're closely watching persistent cost volatility, high demand and continued constraints in lending. These forces are making clients more cautious, and rightfully so. Our focus is on helping them understand and manage their risk exposure early so they can secure financing and move forward with confidence. We're doubling down on collaboration during the planning and pricing phases, ensuring decisions are data-driven, not reactive. It's about smarter investments, not just faster ones. Clayco continues to see strong activity in data centers, artificial intelligence-driven projects, advanced manufacturing and life sciences. The rapid acceleration of AI technologies and the growing demand for data processing have fueled a surge in data center construction, which led to the launch of our newest business unit, Clayco Compute. Another growth area for our company currently is privately developed student housing at some of the major university campuses throughout the country. Our investors continue to be excited for this asset class in core markets. We also are beginning to see a resurgence of multifamily and mixed-use projects in select urban markets throughout the country. We are leaning into high-growth sectors with real staying power, like data centers and advanced tech. Our launch of Clayco Compute wasn't just a new unit, it was a strategic bet on the future of infrastructure, and it's paying off. We also are investing heavily in expanding our engineering, design, and self-perform mechanical and electrical capabilities, giving us more control over critical systems and execution speed. We are experiencing impacts on a couple different fronts, which has positioned us to focus heavily on supply chain and also project underwriting. On one hand, we have companies looking for reshoring opportunities, clients looking to continue to expand their data center businesses and domestic companies looking to continue their expansions already underway. On the other hand, we also have these same clients looking to us to help them navigate the current tariff constraints, potential cost uncertainties and a challenging lending environment. So, in essence, the same company can be both optimistic and growth focused, but also cautious and uncertain about their investment at the same time. We are working closely with these clients to provide complete transparency to our supply chain, help them understand alternates and contingency plans and, in doing so, de-risk their projects. The quest for power is leading many users to more and more remote locations, which makes finding skilled labor an even greater challenge. This trend, in conjunction with the drive for acceleration and speed to market, drives the need for further innovation in project execution. Off and onsite modularization and prefabrication are examples of strategies Clayco is implementing to address these challenges. Recommended Reading New Clayco CEO expects data center boom to thrive Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Novo Nordisk Stock: Is It Still a Smart Buy?
This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran pharmaceutical company, however. 10 stocks we like better than Novo Nordisk › Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight loss drug Wegovy, have fallen nearly 18% in price since the start of this year. Popularity attracts competition, and investors are growing concerned that the Danish pharmaceutical giant won't be able to compete. I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, when Wegovy became the first GLP-1 drug specifically approved by the Food and Drug Administration (FDA) for that indication in mid-2021. Novo Nordisk's Ozempic was first, but it was used off-label as a weight-loss drug, and had only initially been approved as a diabetes treatment and kidney disease treatment. It's easy to believe in a company when it's riding high and unopposed. But late in 2023, a new entrant was approved -- mighty American pharmaceutical company Eli Lilly (NYSE: LLY) with its own GLP-1 treatment, Zepbound -- giving Novo Nordisk one of the strongest competitors imaginable. Almost certainly, this won't continue to be a two-car race for long. Other companies, both large and small, in the healthcare field are pushing hard to develop their own obesity drugs, with varying degrees of success. Eli Lilly alone is an intimidating presence. A mainstay on the American pharmaceutical scene, it's grown to a massive size, to the point where it's the most valuable pharmaceutical company in the world by market cap. It can leverage its vast resources to develop and market any kind of medicine it wants, and in the obesity segment, it was already nearly there with Zepbound's FDA-approved-for-diabetes sibling drug, Mounjaro. Since then, it seems Zepbound has carved out a significant market share from Wegovy. Precise figures are hard to come by, but according to a Goldman Sachs analysis recently reported by Barron's, Novo Nordisk is clinging to a 51% share of the roughly $28 billion market. Eli Lilly holds the rest. Like other pharmaceutical industry pundits, Goldman Sachs is predicting that once other obesity drugs are developed successfully and approved, the market will fragment. That's a wholly believable prediction given the zeal and urgency behind many of those efforts. Meanwhile, Novo Nordisk has taken a series of competitive blows that reduced its lead. A shortage of semaglutide -- the main ingredient of Wegovy -- led the FDA to allow compounding pharmacies to make copies of the molecule, essentially producing new competition. Although the shortage is officially over, it showed that Novo Nordisk would be vulnerable if such a situation reoccurred. Another of the numerous fresh setbacks was a head-to-head clinical trial conducted by Eli Lilly, pitting Zepbound against Wegovy. Last December, the results of the study indicated notably more significant weight loss for participants using Wegovy. One internal development also dented investor sentiment on Novo Nordisk, and that was the company's announcement in mid-May that long-serving CEO Lars Fruergaard Jørgensen was stepping down. When enterprises are humming along pleasantly, they rarely experience a top leader's departure. Novo Nordisk isn't just absorbing hurtful blows, though; it's been busy shoring up its defenses. As 2024 came to a close, it scooped up contract drug manufacturer Catalent, bringing Wegovy production more under its direct control. That $16.5 billion deal wasn't cheap by any yardstick, but if the new asset is managed well, it should be more than worth the cost ultimately. Novo Nordisk is also keeping up the pace with its own development activities, attempting to succeed with new medications and/or other indications for Wegovy. Its next-generation obesity treatment CagriSema was essentially a flop. However, the company has already had success winning FDA approval for the versatile Wegovy to treat liver disorder metabolic dysfunction-associated steatohepatitis (MASH), and it's developing the drug for a clutch of other ailments. It also has other medications for different disorders in its pipeline. Meanwhile, a score of researchers modeling the future of the obesity market feel that sales of such drugs will blast through the roof. Projections vary, but a typical one is the latest from Morgan Stanley. In May, the veteran investment bank upped its estimate for the market's peak (predicted to occur in 2035) to $150 billion, well up from its previous assumption of $105 billion. The former number is more than 6 times the $24 billion estimated sales of 2024. The very encouraging news for Novo Nordisk bulls like myself is that even if the market gets highly fragmented with numerous competing products and loses significantly more share -- unlikely, given its first-mover prominence and the strength of the Wegovy brand name -- it'll still be a player in a huge market. Yes, competition can be tough. There are a lot of prizes in this game, and more players are entering it. But I think this original player will manage to hold on and thrive, and I continue to consider Novo Nordisk stock a buy. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs Group. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Novo Nordisk Stock: Is It Still a Smart Buy? was originally published by The Motley Fool
Yahoo
7 hours ago
- Yahoo
Washington grocery workers may strike following union vote
Jun. 6—The union that represents about 56,000 mostly grocery and health workers across Washington, North Idaho and northeastern Oregon voted Thursday night to authorize a strike of employees working at grocery stores owned by Albertsons and Kroger. The vote, however, simply authorizes a strike and does not immediately call for one. It does not involve workers of Rosauers, Safeway, Albertsons and Fred Meyer in the Spokane area because they authorized a contract that does not expire until next year. Safeway is owned by Albertsons, and Fred Meyer is owned by Kroger. Tom Geiger, special projects director for the United Food and Commercial Workers International Union, or UFCW, said the vote Thursday night mostly involves workers at Albertsons and Kroger stores in Western Washington. "We authorized a strike to fight for better wages, better staffing, and a fully funded health care plan so that we can deliver the kind of service our customers deserve," Vickie Logerstedt, a cashier at Redmond Ridge QFC, said in a news release. "We have been more than patient for months, but these companies have offered nothing but crumbs and mealy language. Time has run out." Efforts to reach the corporate offices of Albertsons, which is based in Boise, and Kroger, based in Cincinnati, were not immediately successful on Friday. The strike-authorization vote follows two major events: The UFCW launched major opposition to the now-failed merger attempt between Albertsons and Kroger, and ongoing contract negotiations for workers in Western Washington, Colorado and California, Geiger said. A federal judge in Oregon and a Washington state judge ruled against the merger in December . The proposal would have been the largest merger of grocery store giants. Had it gone through, it would have led to the loss of Safeway stores on the South Hill and Spokane Valley, based on a previously released list of store sales. The two grocery companies first announced merger plans in 2022 to get bigger to take on retail competitors Amazon and Walmart. That proposal spawned lawsuits from the attorneys general of Washington and Colorado, and the Federal Trade Commission filed a federal suit in Oregon. All sought to block the deal over concerns that it would reduce customer choices and bargaining positions of employees across the country. Then in January, the UFCW began negotiating new contracts for workers of stores in Western Washington for a contract that expired in the first week of May. Geiger said the union and grocery stores agreed to extend the terms of the former contract during negotiations. But talks stalled after the company's offer, said Rich Smith, communications director for the UFCW. "The wages were insulting; staffing is a core issue, and right now they are underfunding the health care," Smith said. Based on that offer, the union put two questions to its membership, Geiger said: whether workers approved the offer, and authorized a strike. Some "97% rejected the offer and voted to authorize the strike," Geiger said. "We feel it is a pretty clear message. Often, they have boiler-plate statements that say, 'We believe the best way to reach a good agreement is at the bargaining table.' We agree. "But we've been at the bargaining table for five months telling the employers what is needed, and they haven't been good listeners." Despite the vote to authorize a strike, the extension of the former contract calls for a 72-hour notice before the workers can begin one, Geiger said. The parties are scheduled to resume talks on a potential new contract. "Hopefully, we'll see something change up next week," Geiger said. Fred Meyer president Todd Kammeyer said in a news release that his company is committed to reaching a balanced and fair agreement with his workers. "A strike at this stage is an unnecessary and disruptive action — especially given the meaningful wage increases and industry-leading healthcare we're offering at the bargaining table," Kammeyer said in the release. "We remain committed to continuing negotiations in good faith and urge union leadership to do the same." While the negotiations are separate, Albertsons workers in Colorado voted on Thursday night to authorize a strike. California worker votes for the strike are continuing. All told, if all the UFCW workers do decide to walk out, it could affect up to 100,000 employees across the western U.S. Joe Mizrahi, secretary-treasurer of UFCW local 3000, the largest private-sector union in Washington, said the support of the strike-authorization votes should serve as a wake-up call.
